Greg Archambeau, President, Revalesio
LinkedIn: Greg Archambeau
LinkedIn: Revalesio
Greg is the co-inventor of RNS60. Prior to being named President in 2016, Greg operated as Revalesio’s VP of Operations where he was responsible for guiding RNS60’s regulatory strategy, designing and commissioning the company’s GMP compliant, clinical manufacturing facility and implementing Revalesio’s Quality Management System. Prior to Revalesio, Greg designed gas/liquid mixing equipment and reactors for Koch Industries. He earned a B.S. in Chemical Engineering from Colorado School of Mines.
Listen to the Conversation
On this episode Jim welcomes Greg Archambeau, President of Revalesio Corporation who discusses RNS60, a novel treatment for both ALS and acute ischemic stroke. Phase 3 trials are beginning soon based on promising Phase 2 results.
About the Show
From border to border and coast to coast and all the ships at sea. Tune in to hear your correspondent Jim Tate on The Tate Chronicles. Join him as he cuts through the fog and static that exists at the leading edge of healthcare technology. Come with him as he explores emerging technologies that hold potential to bring beneficial disruptions to healthcare.
Tune in weekdays at 3:30am, 11:30am, and 7:30pm ET.
Follow the show’s social hashtag #TateDispatches.
